Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 68

1.

Aldoxorubicin in soft tissue sarcomas.

Chamberlain FE, Jones RL, Chawla SP.

Future Oncol. 2019 Mar 15. doi: 10.2217/fon-2018-0922. [Epub ahead of print]

PMID:
30873850
2.

Regorafenib regressed a doxorubicin-resistant Ewing's sarcoma in a patient-derived orthotopic xenograft (PDOX) nude mouse model.

Miyake K, Kiyuna T, Kawaguchi K, Higuchi T, Oshiro H, Zhang Z, Wangsiricharoen S, Razmjooei S, Li Y, Nelson SD, Murakami T, Hiroshima Y, Matsuyama R, Bouvet M, Chawla SP, Singh SR, Endo I, Hoffman RM.

Cancer Chemother Pharmacol. 2019 Feb 13. doi: 10.1007/s00280-019-03782-w. [Epub ahead of print]

PMID:
30758647
3.

Alpha particle Radium 223 dichloride in high-risk osteosarcoma: a phase I dose escalation trial.

Subbiah V, Anderson PM, Kairemo K, Hess KR, Huh WW, Ravi V, Daw NC, Somaiah N, Ludwig JA, Benjamin RS, Chawla SP, Hong DS, Meric-Bernstam F, Ravizzini G, Kleinerman ES, Macapinlac HA, Rohren EM.

Clin Cancer Res. 2019 Feb 7. pii: clincanres.3964.2018. doi: 10.1158/1078-0432.CCR-18-3964. [Epub ahead of print]

PMID:
30733229
4.

A Phase I-II Study Using Rexin-G Tumor-Targeted Retrovector Encoding a Dominant-Negative Cyclin G1 Inhibitor for Advanced Pancreatic Cancer.

Chawla SP, Bruckner H, Morse MA, Assudani N, Hall FL, Gordon EM.

Mol Ther Oncolytics. 2018 Dec 14;12:56-67. doi: 10.1016/j.omto.2018.12.005. eCollection 2019 Mar 29.

5.

Gemcitabine combined with docetaxel precisely regressed a recurrent leiomyosarcoma peritoneal metastasis in a patient-derived orthotopic xenograft (PDOX) model.

Miyake K, Kiyuna T, Miyake M, Kawaguchi K, Zhang Z, Wangsiricharoen S, Razmjooei S, Oshiro H, Higuchi T, Li Y, Nelson SD, Murakami T, Hiroshima Y, Kumamoto T, Matsuyama R, Bouvet M, Singh SR, Chawla SP, Endo I, Hoffman RM.

Biochem Biophys Res Commun. 2019 Feb 19;509(4):1041-1046. doi: 10.1016/j.bbrc.2019.01.046. Epub 2019 Jan 16.

PMID:
30660363
6.

The combination of gemcitabine and nab-paclitaxel as a novel effective treatment strategy for undifferentiated soft-tissue sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse model.

Higuchi T, Kawaguchi K, Miyake K, Oshiro H, Zhang Z, Razmjooei S, Wangsiricharoen S, Igarashi K, Yamamoto N, Hayashi K, Kimura H, Miwa S, Nelson SD, Dry SM, Li Y, Chawla SP, Eilber FC, Singh SR, Tsuchiya H, Hoffman RM.

Biomed Pharmacother. 2019 Mar;111:835-840. doi: 10.1016/j.biopha.2018.12.110. Epub 2019 Jan 4.

7.

Exploiting Oncogenic Drivers along the CCNG1 Pathway for Cancer Therapy and Gene Therapy.

Al-Shihabi A, Chawla SP, Hall FL, Gordon EM.

Mol Ther Oncolytics. 2018 Dec 12;11:122-126. doi: 10.1016/j.omto.2018.11.002. eCollection 2018 Dec 21. Review. No abstract available.

8.

Metabolic targeting with recombinant methioninase combined with palbociclib regresses a doxorubicin-resistant dedifferentiated liposarcoma.

Igarashi K, Kawaguchi K, Kiyuna T, Miyake K, Miyaki M, Yamamoto N, Hayashi K, Kimura H, Miwa S, Higuchi T, Singh AS, Chmielowski B, Nelson SD, Russell TA, Eckardt MA, Dry SM, Li Y, Singh SR, Chawla SP, Eilber FC, Tsuchiya H, Hoffman RM.

Biochem Biophys Res Commun. 2018 Dec 2;506(4):912-917. doi: 10.1016/j.bbrc.2018.10.119. Epub 2018 Nov 2.

PMID:
30392912
9.

Tumor-targeting Salmonella typhimurium A1-R overcomes partial carboplatinum-resistance of a cancer of unknown primary (CUP).

Miyake K, Kiyuna T, Miyake M, Zhao M, Wangsiricharoen S, Kawaguchi K, Zhang Z, Higuchi T, Razmjooei S, Li Y, Nelson SD, Russell T, Singh A, Murakami T, Hiroshima Y, Momiyama M, Matsuyama R, Chishima T, Singh SR, Chawla SP, Eilber FC, Endo I, Hoffman RM.

Tissue Cell. 2018 Oct;54:144-149. doi: 10.1016/j.tice.2018.09.001. Epub 2018 Sep 14.

PMID:
30309504
10.

A combination of irinotecan/cisplatinum and irinotecan/temozolomide or tumor-targeting Salmonella typhimurium A1-R arrest doxorubicin- and temozolomide-resistant myxofibrosarcoma in a PDOX mouse model.

Kiyuna T, Tome Y, Murakami T, Miyake K, Igarashi K, Kawaguchi K, Oshiro H, Higuchi T, Miyake M, Sugisawa N, Zhang Z, Razmjooei S, Wangsiricharoen S, Chmielowski B, Nelson SD, Russell TA, Dry SM, Li Y, Eckardt MA, Singh AS, Chawla S, Kanaya F, Eilber FC, Singh SR, Zhao M, Hoffman RM.

Biochem Biophys Res Commun. 2018 Nov 2;505(3):733-739. doi: 10.1016/j.bbrc.2018.09.106. Epub 2018 Oct 3.

PMID:
30292411
11.

Oral Recombinant Methioninase Combined with Caffeine and Doxorubicin Induced Regression of a Doxorubicin-resistant Synovial Sarcoma in a PDOX Mouse Model.

Higuchi T, Kawaguchi K, Miyake K, Han Q, Tan Y, Oshiro H, Sugisawa N, Zhang Z, Razmjooei S, Yamamoto N, Hayashi K, Kimura H, Miwa S, Igarashi K, Chawla SP, Singh AS, Eilber FC, Singh SR, Tsuchiya H, Hoffman RM.

Anticancer Res. 2018 Oct;38(10):5639-5644. doi: 10.21873/anticanres.12899.

PMID:
30275182
12.

Assessment of denosumab treatment effects and imaging response in patients with giant cell tumor of bone.

Engellau J, Seeger L, Grimer R, Henshaw R, Gelderblom H, Choy E, Chawla S, Reichardt P, O'Neal M, Feng A, Jacobs I, Roberts ZJ, Braun A, Bach BA.

World J Surg Oncol. 2018 Sep 19;16(1):191. doi: 10.1186/s12957-018-1478-3.

13.

Cell cycle checkpoint control: The cyclin G1/Mdm2/p53 axis emerges as a strategic target for broad-spectrum cancer gene therapy - A review of molecular mechanisms for oncologists.

Gordon EM, Ravicz JR, Liu S, Chawla SP, Hall FL.

Mol Clin Oncol. 2018 Aug;9(2):115-134. doi: 10.3892/mco.2018.1657. Epub 2018 Jun 14.

14.

A multicenter phase II study of Q3 week or weekly paclitaxel in combination with bevacizumab for the treatment of metastatic or unresectable angiosarcoma.

Bui N, Kamat N, Ravi V, Chawla S, Lohman M, Ganjoo KN.

Rare Tumors. 2018 Apr 23;10:2036361318771771. doi: 10.1177/2036361318771771. eCollection 2018.

15.

Eribulin therapy for the treatment of patients with advanced soft tissue sarcoma.

Seetharam M, Kolla KR, Chawla SP.

Future Oncol. 2018 Jul;14(16):1531-1545. doi: 10.2217/fon-2017-0461. Epub 2018 Feb 7. Review.

PMID:
29411654
16.

Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine.

Demetri GD, Schöffski P, Grignani G, Blay JY, Maki RG, Van Tine BA, Alcindor T, Jones RL, D'Adamo DR, Guo M, Chawla S.

J Clin Oncol. 2017 Oct 20;35(30):3433-3439. doi: 10.1200/JCO.2016.71.6605. Epub 2017 Aug 30.

PMID:
28854066
17.

Results of a prospective phase 2 study of pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma.

Samuels BL, Chawla SP, Somaiah N, Staddon AP, Skubitz KM, Milhem MM, Kaiser PE, Portnoy DC, Priebat DA, Walker MS, Stepanski EJ.

Cancer. 2017 Dec 1;123(23):4640-4647. doi: 10.1002/cncr.30926. Epub 2017 Aug 18.

18.

Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial.

Tap WD, Papai Z, Van Tine BA, Attia S, Ganjoo KN, Jones RL, Schuetze S, Reed D, Chawla SP, Riedel RF, Krarup-Hansen A, Toulmonde M, Ray-Coquard I, Hohenberger P, Grignani G, Cranmer LD, Okuno S, Agulnik M, Read W, Ryan CW, Alcindor T, Del Muro XFG, Budd GT, Tawbi H, Pearce T, Kroll S, Reinke DK, Schöffski P.

Lancet Oncol. 2017 Aug;18(8):1089-1103. doi: 10.1016/S1470-2045(17)30381-9. Epub 2017 Jun 23. Erratum in: Lancet Oncol. 2018 Feb;19(2):e78.

PMID:
28651927
19.

Eribulin in advanced liposarcoma and leiomyosarcoma.

Setola E, Noujaim J, Benson C, Chawla S, Palmerini E, Jones RL.

Expert Rev Anticancer Ther. 2017 Aug;17(8):717-723. doi: 10.1080/14737140.2017.1344098. Epub 2017 Jun 28. Review.

PMID:
28621163
20.

Rexin-G®, a tumor-targeted retrovector for malignant peripheral nerve sheath tumor: A case report.

Kim S, Federman N, Gordon EM, Hall FL, Chawla SP.

Mol Clin Oncol. 2017 Jun;6(6):861-865. doi: 10.3892/mco.2017.1231. Epub 2017 Apr 28.

Supplemental Content

Loading ...
Support Center